Pheast Therapeutics
PrivateLast Round
Series A
Extension
Oct 15, 2025
Total Funding Raised
$100.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Pheast Therapeutics is a biotechnology company developing novel innate immune checkpoint inhibitors to enhance macrophage-mediated clearance of tumor cells in aggressive cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pheast Therapeutics Comparables
Compare Pheast Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoC4, Inc. | 82% | |
| DEM BioPharma | 80% | |
| Gilead Sciences | 79% |
Pheast Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 15, 2025 | ||||
| Series A | Apr 26, 2022 |
Key People
Founding team and executive leadership
Pheast Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ARCH Venture Partners | Series A |
| Catalio Capital Management | Series A |
| ARCH Venture Partners | Series A |
| Alexandria Venture Investments | Series A |
| Stanford University's Presidential Venture Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 40% MoM.
- Apr 26, 2022
$76M round led by ARCH Venture Partners and Catalio Capital Management.
Recent news
Latest coverage and updates
- is_developingAug 3, 2026
Pheast Therapeutics, Inc. is developing novel therapies for some of the most difficult-to-treat and aggressive cancers.
Pheast Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Pheast Therapeutics's valuation, stock price, and market status.
Is Pheast Therapeutics a public or private company?
Pheast Therapeutics is a private company.
What is the current stock price of Pheast Therapeutics?
Pheast Therapeutics is a private company, so its shares have no public market price. Caplight tracks Pheast Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pheast Therapeutics worth (valuation)?
Valuation information for Pheast Therapeutics is not publicly available.
Can I buy Pheast Therapeutics stock?
Pheast Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pheast Therapeutics's last funding round?
Pheast Therapeutics's most recent funding round was Series A Extension on October 15, 2025.
Who are the main investors in Pheast Therapeutics?
Key investors in Pheast Therapeutics include ARCH Venture Partners, Catalio Capital Management, ARCH Venture Partners.
Will Pheast Therapeutics IPO soon?
No public IPO plans have been announced for Pheast Therapeutics.
How can I track Pheast Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Pheast Therapeutics's shares on secondary markets.